Undifferentiated Pleomorphic Sarcoma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Undifferentiated Pleomorphic Sarcoma Market Outlook

Thelansis’s “Undifferentiated Pleomorphic Sarcoma Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Undifferentiated Pleomorphic Sarcoma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Undifferentiated Pleomorphic Sarcoma Overview

Undifferentiated Pleomorphic Sarcoma (UPS) is a rare and aggressive type of sarcoma that can originate in any body part, including soft tissue and bone. The tumor is most commonly diagnosed in individuals between the ages of 60 and 70, with the most common sites of involvement being the lower extremities, particularly the thigh, upper arms, retroperitoneum, viscera, head, and neck (in childhood cases). High local recurrence rates and significant metastasis typically characterize it. Symptoms of UPS may include swelling, mass, pain, pathological fractures, and systemic features such as anorexia, malaise, fever, and weight loss. Treatment for UPS typically involves wide surgical excision; sometimes, amputation may be necessary to remove the entire lesion. Adjuvant radiotherapy is often given for high-grade, large, deep-seated tumors, in limb-sparing surgeries, and when negative margins are not obtained. Primary radiation therapy may be an option for inoperable sarcomas, but chemotherapy regimens containing doxorubicin are typically preferred in the first-line setting for locally irresectable and metastatic lesions. Chemotherapy with ifosfamide, trabectedin, dacarbazine, and pazopanib has demonstrated efficacy in UPS and is available in most European Union countries. The overall 5-year survival rate for UPS ranges from 48% for patients with head and neck tumors to 77% for patients with tumors arising on the trunk and extremities. The prognosis for the childhood variant of UPS appears to be better than for adult cases.

• The SEER program reports that among 26,758 cases, 17.1% were UPS, making it the second most frequent STS after leiomyosarcoma, regardless of the primary tumor location. Males have a significantly higher incidence rate than females.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: